MAPT and Alzheimer disease: Although conventional biomarkers such as Aβ42 and phospho-tau can detect underlying amyloid and tau pathology in asymptomatic individuals (Niimi et al., 2024), combining them with sensitive behavioral measures may improve the precision and timing of preclinical AD detection.